|

A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours

RECRUITINGPhase 1/2Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Actively Recruiting
PhasePhase 1/2
SponsorSuzhou Zelgen Biopharmaceuticals Co.,Ltd
Started2023-08-10
Est. completion2026-02
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06237413

Summary

This study will evaluate the tolerability, safety, effects, and pharmacokinetics of ZG2001 in Participants with advanced solid tumors that have a KRAS mutation.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Participants who fully understood this study and voluntarily signed the informed consent form;
* Men or women ≥ 18 years old;
* Participants with a KRAS mutant solid tumor should have progressed on or are ineligible for all therapy(ies) known to confer clinical benefit.
* ECOG Performance Status (PS) 0 or 1;
* Life expectancy \> 3 months.

Exclusion Criteria:

* Received any SOS1 inhibitors;
* Participants with a known history of hypersensitivity reactions to the ingredients of the preparations used in this study;
* Other conditions that the investigator considers to be unsuitable for participation in this study.

Conditions3

CancerKRAS Mutation-Related TumorsSolid Tumor

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.